Literature DB >> 22089066

Hyperparathyroidism: primary or secondary disease?

Isabel Martínez Cordellat1.   

Abstract

Primary hyperparathyroidism (PHPT) is characterized by the autonomous production of parathyroid hormone (PTH), in which there is hypercalcemia or normal-high serum calcium levels in the presence of elevated or inappropriately normal serum PTH concentrations. Exceptionally in symptomatic patients, a diagnostic can be established on the basis of clinical data. PHPT must always be evaluated in patients with clinical histories of nephrolithiasis, nephrocalcinosis, osseous pain, subperiosteal resorption, and pathologic fractures, as well as in those with osteoporosis-osteopenia, a personal history of neck irradiation, or a family history of multiple endocrine neoplasia syndrome (types 1 or 2). Diagnosis of PHPT is biochemical. Asymptomatic hypercalcemia without guiding signs or symptoms is the most frequent manifestation of the disease. For differential diagnosis, PTH must be measured, as well as phosphate, chloride, 25-hydroxyvitamin D, 1,25 dyhidroxyvitamin D and calcium-to-creatinine clearance. The diagnosis and differential diagnosis of primary hyperparathyroidism will be discussed here.
Copyright © 2011 Elsevier España, S.L. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22089066     DOI: 10.1016/j.reuma.2011.06.001

Source DB:  PubMed          Journal:  Reumatol Clin        ISSN: 1699-258X


  8 in total

Review 1.  Primary hyperparathyroidism.

Authors:  Tarıq Madkhali; Amal Alhefdhi; Herbert Chen; Dawn Elfenbein
Journal:  Ulus Cerrahi Derg       Date:  2016-03-01

2.  Superior performance of 18F-fluorocholine digital PET/CT in the detection of parathyroid adenomas.

Authors:  Diego Alfonso López-Mora; Marina Sizova; Montserrat Estorch; Albert Flotats; Valle Camacho; Alejandro Fernández; Safae Abouzian; Francisco Fuentes-Ocampo; José Ignacio Pérez Garcia; Ana Isabel Chico Ballesteros; Joan Duch; Anna Domènech; Antonio Moral Duarte; Ignasi Carrió
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-01-09       Impact factor: 9.236

Review 3.  Systemic diseases and the cornea.

Authors:  Ruchi Shah; Cynthia Amador; Kati Tormanen; Sean Ghiam; Mehrnoosh Saghizadeh; Vaithi Arumugaswami; Ashok Kumar; Andrei A Kramerov; Alexander V Ljubimov
Journal:  Exp Eye Res       Date:  2021-01-21       Impact factor: 3.467

4.  Surgical management of a giant parathyroid adenoma through minimal invasive parathyroidectomy. A case report.

Authors:  Georgios Sahsamanis; Konstantinos Gkouzis; Stavros Samaras; Dionysios Pinialidis; Georgios Dimitrakopoulos
Journal:  Int J Surg Case Rep       Date:  2017-01-31

5.  Establish pre-clinical diagnostic efficacy for parathyroid hormone as a point-of-surgery-testing-device (POST).

Authors:  Ambalika S Tanak; Sriram Muthukumar; Ibrahim A Hashim; Shalini Prasad
Journal:  Sci Rep       Date:  2020-11-02       Impact factor: 4.379

6.  Real-world evidence and optimization of vocal dysfunction in end-stage renal disease patients with secondary hyperparathyroidism.

Authors:  Geng-He Chang; Fong-Fu Chou; Ming-Shao Tsai; Yao-Te Tsai; Ming-Yu Yang; Ethan I Huang; Hui-Chen Su; Cheng-Ming Hsu
Journal:  Sci Rep       Date:  2021-01-12       Impact factor: 4.379

7.  Giant Parathyroid Adenoma-Associated Fracture, Not All Lytic Bone Lesions are Cancer: A Case-Based Review.

Authors:  Jose C Alvarez-Payares; Marcel E Ribero; Sara Ramírez-Urrea; María C Fragozo-Ramos; Jose E Agámez-Gómez; Alejandro Román-González; Luis F Arias; Roberto Benavides Arenas; Fernando López-Urbano
Journal:  Case Rep Med       Date:  2022-01-29

Review 8.  Advances in the diagnosis and the management of primary hyperparathyroidism.

Authors:  Ana Kashfia Islam
Journal:  Ther Adv Chronic Dis       Date:  2021-06-11       Impact factor: 5.091

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.